Revisión sistemática de amplio alcance: Seguridad y efectividad de los métodos de anticoncepción hormonal versus métodos de anticoncepción no hormonal o no uso de métodos de anticoncepción para mujeres en edad reproductiva con deseo de fertilidad futura y alto riesgo cardiovascular

ilustraciones, diagramas, tablas

Autores:
Losada Trujillo, Natalia
Tipo de recurso:
Fecha de publicación:
2023
Institución:
Universidad Nacional de Colombia
Repositorio:
Universidad Nacional de Colombia
Idioma:
spa
OAI Identifier:
oai:repositorio.unal.edu.co:unal/86465
Acceso en línea:
https://repositorio.unal.edu.co/handle/unal/86465
https://repositorio.unal.edu.co/
Palabra clave:
100 - Filosofía y Psicología::107 - Educación, investigación, temas relacionados
500 - Ciencias naturales y matemáticas::507 - Educación, investigación, temas relacionados
610 - Medicina y salud::616 - Enfermedades
610 - Medicina y salud::618 - Ginecología, obstetricia, pediatría, geriatría
610 - Medicina y salud::613 - Salud y seguridad personal
610 - Medicina y salud::615 - Farmacología y terapéutica
600 - Tecnología (Ciencias aplicadas)::607 - Educación, investigación, temas relacionados
Anticonceptivos Femeninos
Anticoncepción Hormonal
Factores de Riesgo de Enfermedad Cardiaca
Contraceptive Agents, Female
Hormonal Contraception
Heart Disease Risk Factors
Hipertensión arterial
Anticoncepción hormonal
Seguridad
Efectividad
Hypertension
Hormonal contraception
Safety
Effectiveness
Rights
openAccess
License
Atribución-NoComercial-SinDerivadas 4.0 Internacional
id UNACIONAL2_1c7e1391ba0e38147fb9d82ebd6a50f5
oai_identifier_str oai:repositorio.unal.edu.co:unal/86465
network_acronym_str UNACIONAL2
network_name_str Universidad Nacional de Colombia
repository_id_str
dc.title.spa.fl_str_mv Revisión sistemática de amplio alcance: Seguridad y efectividad de los métodos de anticoncepción hormonal versus métodos de anticoncepción no hormonal o no uso de métodos de anticoncepción para mujeres en edad reproductiva con deseo de fertilidad futura y alto riesgo cardiovascular
dc.title.translated.eng.fl_str_mv Systematic review of broad scope: Safety and effectiveness of hormonal contraception methods versus non-hormonal contraception methods or non-use of contraception methods for women of reproductive age with desire for future fertility and high cardiovascular risk
title Revisión sistemática de amplio alcance: Seguridad y efectividad de los métodos de anticoncepción hormonal versus métodos de anticoncepción no hormonal o no uso de métodos de anticoncepción para mujeres en edad reproductiva con deseo de fertilidad futura y alto riesgo cardiovascular
spellingShingle Revisión sistemática de amplio alcance: Seguridad y efectividad de los métodos de anticoncepción hormonal versus métodos de anticoncepción no hormonal o no uso de métodos de anticoncepción para mujeres en edad reproductiva con deseo de fertilidad futura y alto riesgo cardiovascular
100 - Filosofía y Psicología::107 - Educación, investigación, temas relacionados
500 - Ciencias naturales y matemáticas::507 - Educación, investigación, temas relacionados
610 - Medicina y salud::616 - Enfermedades
610 - Medicina y salud::618 - Ginecología, obstetricia, pediatría, geriatría
610 - Medicina y salud::613 - Salud y seguridad personal
610 - Medicina y salud::615 - Farmacología y terapéutica
600 - Tecnología (Ciencias aplicadas)::607 - Educación, investigación, temas relacionados
Anticonceptivos Femeninos
Anticoncepción Hormonal
Factores de Riesgo de Enfermedad Cardiaca
Contraceptive Agents, Female
Hormonal Contraception
Heart Disease Risk Factors
Hipertensión arterial
Anticoncepción hormonal
Seguridad
Efectividad
Hypertension
Hormonal contraception
Safety
Effectiveness
title_short Revisión sistemática de amplio alcance: Seguridad y efectividad de los métodos de anticoncepción hormonal versus métodos de anticoncepción no hormonal o no uso de métodos de anticoncepción para mujeres en edad reproductiva con deseo de fertilidad futura y alto riesgo cardiovascular
title_full Revisión sistemática de amplio alcance: Seguridad y efectividad de los métodos de anticoncepción hormonal versus métodos de anticoncepción no hormonal o no uso de métodos de anticoncepción para mujeres en edad reproductiva con deseo de fertilidad futura y alto riesgo cardiovascular
title_fullStr Revisión sistemática de amplio alcance: Seguridad y efectividad de los métodos de anticoncepción hormonal versus métodos de anticoncepción no hormonal o no uso de métodos de anticoncepción para mujeres en edad reproductiva con deseo de fertilidad futura y alto riesgo cardiovascular
title_full_unstemmed Revisión sistemática de amplio alcance: Seguridad y efectividad de los métodos de anticoncepción hormonal versus métodos de anticoncepción no hormonal o no uso de métodos de anticoncepción para mujeres en edad reproductiva con deseo de fertilidad futura y alto riesgo cardiovascular
title_sort Revisión sistemática de amplio alcance: Seguridad y efectividad de los métodos de anticoncepción hormonal versus métodos de anticoncepción no hormonal o no uso de métodos de anticoncepción para mujeres en edad reproductiva con deseo de fertilidad futura y alto riesgo cardiovascular
dc.creator.fl_str_mv Losada Trujillo, Natalia
dc.contributor.advisor.none.fl_str_mv Gaitán Duarte, Hernando
Estrada Orozco, Kelly Patricia
dc.contributor.author.none.fl_str_mv Losada Trujillo, Natalia
dc.contributor.orcid.spa.fl_str_mv Losada Trujillo, Natalia [0000-0002-8682-4072]
dc.contributor.cvlac.spa.fl_str_mv Losada-Trujillo, Natalia
dc.contributor.researchgate.spa.fl_str_mv Losada-Trujillo, Natalia
dc.contributor.googlescholar.spa.fl_str_mv Losada-Trujillo, Natalia
dc.subject.ddc.spa.fl_str_mv 100 - Filosofía y Psicología::107 - Educación, investigación, temas relacionados
500 - Ciencias naturales y matemáticas::507 - Educación, investigación, temas relacionados
610 - Medicina y salud::616 - Enfermedades
610 - Medicina y salud::618 - Ginecología, obstetricia, pediatría, geriatría
610 - Medicina y salud::613 - Salud y seguridad personal
610 - Medicina y salud::615 - Farmacología y terapéutica
600 - Tecnología (Ciencias aplicadas)::607 - Educación, investigación, temas relacionados
topic 100 - Filosofía y Psicología::107 - Educación, investigación, temas relacionados
500 - Ciencias naturales y matemáticas::507 - Educación, investigación, temas relacionados
610 - Medicina y salud::616 - Enfermedades
610 - Medicina y salud::618 - Ginecología, obstetricia, pediatría, geriatría
610 - Medicina y salud::613 - Salud y seguridad personal
610 - Medicina y salud::615 - Farmacología y terapéutica
600 - Tecnología (Ciencias aplicadas)::607 - Educación, investigación, temas relacionados
Anticonceptivos Femeninos
Anticoncepción Hormonal
Factores de Riesgo de Enfermedad Cardiaca
Contraceptive Agents, Female
Hormonal Contraception
Heart Disease Risk Factors
Hipertensión arterial
Anticoncepción hormonal
Seguridad
Efectividad
Hypertension
Hormonal contraception
Safety
Effectiveness
dc.subject.decs.spa.fl_str_mv Anticonceptivos Femeninos
Anticoncepción Hormonal
Factores de Riesgo de Enfermedad Cardiaca
dc.subject.decs.eng.fl_str_mv Contraceptive Agents, Female
Hormonal Contraception
Heart Disease Risk Factors
dc.subject.proposal.spa.fl_str_mv Hipertensión arterial
Anticoncepción hormonal
Seguridad
Efectividad
dc.subject.proposal.eng.fl_str_mv Hypertension
Hormonal contraception
Safety
Effectiveness
description ilustraciones, diagramas, tablas
publishDate 2023
dc.date.issued.none.fl_str_mv 2023
dc.date.accessioned.none.fl_str_mv 2024-07-16T17:40:11Z
dc.date.available.none.fl_str_mv 2024-07-16T17:40:11Z
dc.type.spa.fl_str_mv Trabajo de grado - Maestría
dc.type.driver.spa.fl_str_mv info:eu-repo/semantics/masterThesis
dc.type.version.spa.fl_str_mv info:eu-repo/semantics/acceptedVersion
dc.type.content.spa.fl_str_mv Text
dc.type.redcol.spa.fl_str_mv http://purl.org/redcol/resource_type/TM
status_str acceptedVersion
dc.identifier.uri.none.fl_str_mv https://repositorio.unal.edu.co/handle/unal/86465
dc.identifier.instname.spa.fl_str_mv Universidad Nacional de Colombia
dc.identifier.reponame.spa.fl_str_mv Repositorio Institucional Universidad Nacional de Colombia
dc.identifier.repourl.spa.fl_str_mv https://repositorio.unal.edu.co/
url https://repositorio.unal.edu.co/handle/unal/86465
https://repositorio.unal.edu.co/
identifier_str_mv Universidad Nacional de Colombia
Repositorio Institucional Universidad Nacional de Colombia
dc.language.iso.spa.fl_str_mv spa
language spa
dc.relation.references.spa.fl_str_mv 1. Grupo Banco Mundial BIRF- AIF [Internet]. [citado 7 de octubre de 2023]. Banco Mundial: Esperanza de vida al nacer. Disponible en: https://data.worldbank.org
2. Wang H, Naghavi M, Allen C, Barber RM, Carter A, Casey DC, et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet [Internet]. octubre de 2016;388(10053):1459-544. Disponible en: http://www.thelancet.com/article/S0140673616310121/fulltext
3. Mathews TJ, Hamilton BE. First births to older women continue to rise. NCHS data brief, no 152. [Internet]. National Center for Health Statistics. 2014 [citado 14 de enero de 2022]. Disponible en: https://www.cdc.gov/nchs/products/databriefs/db152.htm
4. Organización para la Cooperación y el Desarrollo Económicos. Age of mothers at childbirth and age-specific fertility. OECD [Internet]. 2021; Disponible en: https://doi.org/10.25318/1310041801-eng
5. Organization WH. Global Health Estimates 2016: Deaths by Cause, Age, Sex, by Country and by Region, 2000–2016. En: World Health Organization. Geneva; 2016.
6. Global burden of disease U of W. Data Visualizations Institute for Health Metrics and Evaluation [Internet]. 2021 [citado 6 de diciembre de 2021]. Disponible en: http://www.healthdata.org/results/data-visualizations
7. Hui L. Assessment of the role of ageing and non-ageing factors in death from non-communicable diseases based on a cumulative frequency model. Sci Rep 2017 71 [Internet]. agosto de 2017;7(1):1-7. Disponible en: https://www.nature.com/articles/s41598-017-08539-0
8. International Federation of Gynecology and Obstetrics (FIGO). Pregnancy: Risks and Complications, Figo [Internet]. 2021 [citado 28 de diciembre de 2021]. Disponible en: https://www.figo.org/pregnancy-risks-and-complications
9. Parikh NI, Gonzalez JM, Anderson CAM, Judd SE, Rexrode KM, Hlatky MA, et al. Adverse Pregnancy Outcomes and Cardiovascular Disease Risk: Unique Opportunities for Cardiovascular Disease Prevention in Women: A Scientific Statement From the American Heart Association. Circulation [Internet]. 2021;143:E902-16. Disponible en: https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000000961
10. World Health Organization. Cardiovascular diseases (CVDs) [Internet]. 2021 [citado 6 de diciembre de 2021]. Disponible en: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
11. Centers for Disease Control and Prevention (CDC). Cardiovascular Diseases [Internet]. Division of Global Health Protection. 2021 [citado 6 de diciembre de 2021]. Disponible en: https://www.cdc.gov/globalhealth/healthprotection/ncd/cardiovascular-diseases.html
12. Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscalzo J. Harrison Principios de medicina interna. 19.a ed. Graw M, editor. United States of America; 2016. 467–2770 p.
13. Organisation for economic co-operation and development. OECD.Stat. [citado 7 de octubre de 2023]. Organisation for economic co-operation and development: Family Database. Disponible en: https://stats.oecd.org/Index.aspx?DataSetCode=FAMILY
14. Pan American Health Organization, World Health Organization. Noncommunicable Diseases - PAHO/WHO [Internet]. 2021 [citado 6 de diciembre de 2021]. Disponible en: https://www.paho.org/en/topics/noncommunicable-diseases
15. World Health Organization. Noncommunicable diseases [Internet]. Noncommunicable disease. 2021 [citado 6 de diciembre de 2021]. Disponible en: https://www.who.int/health-topics/noncommunicable-diseases#tab=tab_1
16. Division of Reproductive Health NC for CDP, Promotion H, Centers for Disease Control and Prevention. Unintended Pregnancy, Reproductive Health [Internet]. CDC. 2021 [citado 15 de enero de 2022]. Disponible en: https://www.cdc.gov/reproductivehealth/contraception/unintendedpregnancy/index.htm
17. World Health Organization. Contraception [Internet]. World Health Organization. 2022 [citado 15 de enero de 2022]. Disponible en: https://www.who.int/health-topics/contraception#tab=tab_1
18. United Nations Department of Economic and Social Affairs PD. World Family Planning 2020 Highlights: Accelerating action to ensure universal access to family planning (ST/ESA/SER.A/450) [Internet]. United Nations, Department of Economic and Social Affairs, editores. United Nations. 2020. Disponible en: https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/files/documents/2020/Sep/unpd_2020_worldfamilyplanning_highlights.pdf/
19. World Health Organization. Women of reproductive age (15-49 years) population (thousands) [Internet]. The global health observatory. 2021 [citado 6 de diciembre de 2021]. Disponible en: https://www.who.int/data/gho/indicator-metadata-registry/imr-details/women-of-reproductive-age-(15-49-years)-population-(thousands)
20. World Health Organization. Reproductive Health indicators Guidelines for their generation, interpretation and analysis for global monitoring. WHO Library Cataloguing-in-Publication Data, editor. Vol. 1, World Health Organization. Geneva: World Health Organization; 2006. 1–69 p.
21. United Nations, Department of Economic and Social Affairs. Contraceptive Use by Method 2019 Data Booklet. U N [Internet]. 2019; Disponible en: https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/files/documents/2020/Jan/un_2019_contraceptiveusebymethod_databooklet.pdf
22. Ministerio de salud, Profamilia. Encuesta Nacional de Demografía y Salud 2015, Componente de salud sexual y salud reproductiva [Internet]. 1.a ed. Vol. 2. Bogotá; 2015. Disponible en: https://profamilia.org.co/wp-content/uploads/2019/05/ENDS-2015-TOMO-II.pdf
23. Curtis KM, Chrisman CE, Peterson HB, WHO Programme for Mapping Best Practices in Reproductive Health. Contraception for women in selected circumstances. Obstet Gynecol. junio de 2002;99(6):1100-12.
24. Curtis KM, Mohllajee AP, Martins SL, Peterson HB. Combined oral contraceptive use among women with hypertension: A systematic review. Contraception. 2006;73(2):179-88.
25. Organization WH. Noncommunicable diseases country profiles 2018 [Internet]. World Health Organization. 2018 [citado 6 de diciembre de 2021]. Disponible en: https://apps.who.int/iris/handle/10665/274512
26. World Health Organization. Total NCD mortality rate (per 100 000 population) , age-standardized [Internet]. The global health observatory. 2021 [citado 6 de diciembre de 2021]. Disponible en: https://www.who.int/data/gho/data/indicators/indicator-details/gho/gho-ghe-ncd-mortality-rate
27. Bosco E, Hsueh L, McConeghy KW, Gravenstein S, Saade E. Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review. BMC Med Res Methodol 2021 211 [Internet]. noviembre de 2021;21(1):1-18. Disponible en: https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/s12874-021-01440-5
28. Medicines Agency E. Reflection paper on assessment of cardiovascular safety profile of medicinal products. Comm Med Prod Hum Use CHMP [Internet]. 2016; Disponible en: https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-assessment-cardiovascular-safety-profile-medicinal-products_en.pdf
29. Food and Drug Administration (FDA). FDA Background Document Endocrinologic and Metabolic Drugs Advisory Committee Meeting. FDA [Internet]. 2018; Disponible en: https://www.fda.gov/media/121272/download
30. Petitti DB, Sidney S, Quesenberry CP, Bernstein A. Incidence of stroke and myocardial infarction in women of reproductive age. Stroke [Internet]. 1997;28(2):280-3. Disponible en: https://www.ahajournals.org/doi/abs/10.1161/01.str.28.2.280
31. Centers for Disease Control and Prevention. NHANES - National Health and Nutrition Examination Survey 2013–2016 [Internet]. Unpublished National Heart, Lung Unpublished National Heart, Lung, and Blood Institute. 2016 [citado 18 de enero de 2022]. Disponible en: https://www.cdc.gov/nchs/nhanes/index.htm
32. Chopra H, Nanda N, Narula J, Wander G. Hypertension: New Frontiers: A Textbook of Cardiology [Internet]. Jaypee. 2021 [citado 6 de diciembre de 2021]. p. 1. Disponible en: https://books.google.com.co/books?id=_gFBEAAAQBAJ&pg=PR31&lpg=PR31&dq=CVD+MACE+MAKE&source=bl&ots=gp5j_j5qyn&sig=ACfU3U0NpXDhtlIx3aL34DDNysTtWaydUw&hl=es&sa=X&ved=2ahUKEwi39Oz6t870AhWaVzABHQYrDT8Q6AF6BAgQEAM#v=onepage&q=CVD MACE MAKE&f=false
33. Beevers G, Lip GYH, O’brien E. ABC of hypertension: The pathophysiology of hypertension. Br Med J [Internet]. abril de 2001;322(7291):912. Disponible en: /pmc/articles/PMC1120075/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1120075/
34. Stergiou GS, Palatini P, Parati G, O’Brien E, Januszewicz A, Lurbe E, et al. 2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. J Hypertens [Internet]. julio de 2021;39(7):1293-302. Disponible en: https://journals.lww.com/jhypertension/Fulltext/2021/07000/2021_European_Society_of_Hypertension_practice.5.aspx
35. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension [Internet]. junio de 2020;75(6):1334-57. Disponible en: http://ahajournals.org
36. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J [Internet]. septiembre de 2018;39(33):3021-104. Disponible en: https://academic.oup.com/eurheartj/article/39/33/3021/5079119
37. National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management, NICE guideline [Internet]. NICE. 2019 [citado 20 de diciembre de 2021]. Disponible en: https://www.nice.org.uk/guidance/ng136/chapter/Recommendations#diagnosing-hypertension
38. Ostchega Y, Fryar CD, Nwankwo T, Nguyen DT. Hypertension Prevalence Among Adults Aged 18 and Over: United States, 2017-2018 Key findings Data from the National Health and Nutrition Examination Survey. Natl Cent Health Stat [Internet]. 2017; Disponible en: https://www.cdc.gov/nchs/products/databriefs/db364.htm
39. Luo D, Cheng Y, Zhang H, Ba M, Chen P, Li H, et al. Association between high blood pressure and long term cardiovascular events in young adults: Systematic review and meta-analysis. The BMJ. 2020;370.
40. Mockus Sivickas I, Trujillo Güiza ML. Obesidad y enfermedades asociadas. Universida. Universidad Nacional de Colombia, editor. Bogotá D.C., Colombia: Universidad Nacional de Colombia; 2013. 1–206 p.
41. World Health Organization. Global action plan for the prevention and control of noncommunicable diseases 2013-2020. World Health Organ [Internet]. 2013;102. Disponible en: http://apps.who.int/iris/bitstream/10665/94384/1/9789241506236_eng.pdf
42. World Health Organization. Medical eligibility criteria for contraceptive use. 5.a ed. WHO Library Cataloguing-in-Publication Data, editor. Geneva: World Health Organization; 2015. 1–276 p.
43. Quarini CA. History of contraception. Womens Health Med [Internet]. septiembre de 2005;2(5):28-30. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S1744187006000874
44. World Health Organization Department of Reproductive Health and Research (WHO/RHR), Johns Hopkins Bloomberg School of Public Health/Center for Communication Program. Family Planning: A Global Handbook for Providers [Internet]. Baltimore and Geneva; 2022. 1–460 p. Disponible en: https://fphandbook.org/sites/default/files/WHO-JHU-FPHandbook-2022Ed-v221114b.pdf
45. Organización Mundial de la Salud. Planificación familiar [Internet]. Organización Mundial de la Salud. 2020 [citado 21 de enero de 2022]. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/family-planning-contraception
46. Profamilia. Profamilia. [citado 11 de octubre de 2023]. Anticonceptivos orales. Disponible en: https://profamilia.org.co/productos/anticonceptivos-orales/
47. World Health Organization. World Health Organization. [citado 9 de octubre de 2023]. Family planning/contraception methods. Disponible en: https://www.who.int/news-room/fact-sheets/detail/family-planning-contraception
48. Centers for Disease Control and Prevention. CDC. 2023 [citado 9 de octubre de 2023]. Contraception. Disponible en: https://www.cdc.gov/reproductivehealth/contraception/index.htm
49. Bergendal A, Persson I, Odeberg J, Sundström A, Holmström M, Schulman S, et al. Association of venous thromboembolism with hormonal contraception and thrombophilic genotypes. Obstet Gynecol. septiembre de 2014;124(3):600-9.
50. Dinger J, Assmann A, Möhner S, Minh TD. Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study. J Fam Plann Reprod Health Care. julio de 2010;36(3):123-9.
51. Farmer RD, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet Lond Engl. 11 de enero de 1997;349(9045):83-8.
52. Vademecum. Implanon NXT Implante 68 mg [Internet]. 2020 [citado 8 de diciembre de 2021]. Disponible en: https://www.vademecum.es/equivalencia-lista-implanon+nxt-colombia-g03ac08-19002715-co_1
53. Vademecum. Jadelle Implante 75 mg [Internet]. 2015 [citado 8 de diciembre de 2021]. Disponible en: https://www.vademecum.es/equivalencia-lista-jadelle+implante+75+mg-colombia-g03ac03-19002680-co_1
54. Vademecum. Norplant ii implant 75 mg [Internet]. 2015 [citado 8 de diciembre de 2021]. Disponible en: https://www.vademecum.es/equivalencia-lista-norplant+ii+implant+75+mg--g03ac03--_1
55. Profamilia. Profamilia. [citado 7 de octubre de 2023]. Píldoras anticonceptivas de emergencia. Disponible en: https://profamilia.org.co/productos/anticonceptivos-de-emergencia/
56. Vademecum. Mirena Sistema de liberación intrauterino 20 µg/24 h de Colombia [Internet]. 2018 [citado 7 de diciembre de 2021]. Disponible en: https://www.vademecum.es/equivalencia-lista-mirena+sistema+de+liberacion+intrauterino+20+µg%2F24+h-colombia-g02ba03-19002682-co_1
57. Hassoun D. Méthodes de contraception naturelle et méthodes barrières. RPC contraception CNGOF. Gynécologie Obstétrique Fertil Sénologie. diciembre de 2018;46(12):873-82.
58. Brabaharan S, Veettil SK, Kaiser JE, Raja Rao VR, Wattanayingcharoenchai R, Maharajan M, et al. Association of Hormonal Contraceptive Use With Adverse Health Outcomes. JAMA Netw Open [Internet]. enero de 2022;5(1):e2143730. Disponible en: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2788119
59. Lidegaard Ø, Edström B, Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception [Internet]. 1 de marzo de 2002 [citado 7 de octubre de 2023];65(3):187-96. Disponible en: https://www.sciencedirect.com/science/article/pii/S0010782401003079
60. Heinemann LA, Lewis MA, Spitzer WO, Thorogood M, Guggenmoos-Holzmann I, Bruppacher R. Thromboembolic stroke in young women. A European case-control study on oral contraceptives. Transnational Research Group on Oral Contraceptives and the Health of Young Women. Contraception. enero de 1998;57(1):29-37.
61. Lewis MA, Heinemann LAJ, Spitzer WO, MacRae KD, Bruppacher R. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women: Results from the transnational study on oral contraceptives and the health of young women. Contraception [Internet]. 1 de septiembre de 1997 [citado 7 de octubre de 2023];56(3):129-40. Disponible en: https://www.sciencedirect.com/science/article/pii/S0010782497001182
62. Beller FK, Ebert C. Effects of oral contraceptives on blood coagulation. A review. Obstet Gynecol Surv. julio de 1985;40(7):425-36.
63. Notelovitz M. Oral contraception and coagulation. Clin Obstet Gynecol. marzo de 1985;28(1):73-83.
64. Bonnar J. Coagulation effects of oral contraception. Am J Obstet Gynecol. octubre de 1987;157(4 Pt 2):1042-8.
65. Jakes A, Coad F, Nelson-Piercy C. A review of contraceptive methods for women with cardiac disease. Obstet Gynaecol. 28 de enero de 2018;20:21-9.
66. Cilia La Corte AL, Carter AM, Turner AJ, Grant PJ, Hooper NM. The bradykinin-degrading aminopeptidase P is increased in women taking the oral contraceptive pill. J Renin-Angiotensin-Aldosterone Syst JRAAS. diciembre de 2008;9(4):221-5.
67. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Establishing Effectiveness and Safety for Hormonal Drug Products Intended to Prevent Pregnancy Guidance for Industry. Clinical/Medical [Internet]. 2019;1-9. Disponible en: https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm
68. Harvard: School of Public Health. Obesity Prevention Source. 2012 [citado 7 de octubre de 2023]. Measuring Obesity. Disponible en: https://www.hsph.harvard.edu/obesity-prevention-source/obesity-definition/how-to-measure-body-fatness/
69. Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol [Internet]. enero de 2017;112(1):18-35. Disponible en: https://journals.lww.com/ajg/Fulltext/2017/01000/ACG_Clinical_Guideline__Evaluation_of_Abnormal.13.aspx
70. Pagana K, Pagana T, Pagana T. Mosby’s® Diagnostic and Laboratory Test Reference. 15.a ed. Elsevier, editor. United States of America: Elsevier; 2020. 1095 p.
71. Mourad O, Hossam H, Zbys F, Ahmed E. Rayyan — a web and mobile app for systematic reviews [Internet]. 2016. (Systematic Reviews). Disponible en: DOI: 10.1186/s13643-016-0384-4
72. REDCap [Internet]. [citado 18 de octubre de 2023]. Disponible en: https://www.project-redcap.org/
73. Collaboration TC. Review Manager (RevMan) [Internet]. 2020. Disponible en: https://training.cochrane.org/online-learning/core-software-cochrane-reviews/revman/revman-5-download/download-and-installation
74. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ [Internet]. octubre de 2016;355. Disponible en: https://www.bmj.com/content/355/bmj.i4919 https://www.bmj.com/content/355/bmj.i4919.abstract
75. Wells G, Shea B, O’Connell D, Peterson J, Welch V. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis [Internet]. The Ottawa Hospital. 2011 [citado 15 de marzo de 2022]. Disponible en: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
76. Munn Z, Barker T, Moola S, Tufanaru C, Stern C, McArthur A, et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evidence Synthesis. 2020;18(10):2127-33.
77. Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, et al. Chapter 7: Systematic reviews of etiology and risk. JBI Evidence Synthesis [Internet]. 2020; Disponible en: https://jbi.global/critical-appraisal-tools
78. Deeks JJ, Higgins JPT, Altman DG. Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021) [Internet]. Cochrane. 2021 [citado 30 de enero de 2022]. Disponible en: https://training.cochrane.org/handbook/current/chapter-10#section-10-10
79. Stata. Stata 15 [Internet]. Stata. 2017 [citado 15 de marzo de 2022]. Disponible en: https://www.stata.com/stata15/
80. Kevin M S, Andrew G D. EpiInformatics.com. [citado 17 de octubre de 2023]. OpenEpi: Open Source Epidemiologic Statistics for Public Health. Disponible en: https://www.openepi.com/TwobyTwo/TwobyTwo.htm
81. McKenzie JE, Brennan SE, Ryan RE, Thomson HJ, Johnston RV. Chapter 9: Summarizing study characteristics and preparing for synthesis. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021) [Internet]. Cochrane. 2021 [citado 30 de enero de 2022]. Disponible en: https://training.cochrane.org/handbook/current/chapter-09
82. Schünemann H, Brozek J, Guyatt G, Oxman A. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) [Internet]. Grading of Recommendations, Assessment, Development and Evaluation (GRADE) Working Group. GRADE; 2013. Disponible en: https://gdt.gradepro.org/app/handbook/handbook.html
83. University M. GRADEpro GDT [Internet]. Hamilton (ON): McMaster University (developed by Evidence Prime); Disponible en: gradepro.org
84. Ministerio de salud y protección social. Resolución 8430 de 1993 del Ministerio de Salud. 1993. p. 19.
85. Adler TE, Usselman CW, Takamata A, Stachenfeld NS. Blood pressure predicts endothelial function and the effects of ethinyl estradiol exposure in young women. Am J Physiol Heart Circ Physiol. 1 de octubre de 2018;315(4):H925-33.
86. Ananijevic-Pandey J, Vlajinac H. Myocardial Infarction in Young Women with Reference to Oral Contraceptive Use. International Journal of Epidemiology. 1989;4.
87. Andrews J. Hormonal contraceptives with ethinyl estradiol were associated with increased thrombotic stroke and MI. ACP Journal Club. 2012;157(8).
88. Correia P, Machado S, Eskandari A, Michel P. Ischemic stroke in women using contraceptives: Causes, characteristics and outcome. Int J Stroke [Internet]. octubre de 2016 [citado 27 de mayo de 2023];11(3_suppl):4-288. Disponible en: http://journals.sagepub.com/doi/10.1177/1747493016670567
89. Dinger J, Assmann A, Moehner S. Long-term active surveillance study for oral contraceptives (LASS): Impact of oral contraceptive use on the start of antihypertensive treatment. Pharmacoepidemiol Drug Saf. 2010;19:S232.
90. Alcalde Dominguez A, Rabasa Antonijuan J, Cusidó Gimferrer M, Ortuño MJ. Therapy with Ulipristal Acetate in a Hypertensive Patient. Case Rep Med. 2018;2018:1091520.
91. Dong W, Colhoun HM, Poulter NR. Blood pressure in women using oral contraceptives: results from the Health Survey for England 1994. J Hypertens. octubre de 1997;15(10):1063-8.
92. Dunn NR, Arscott A, Thorogood M. The relationship between use of oral contraceptives and myocardial infarction in young women with fatal outcome, compared to those who survive: results from the MICA case-control study. Contraception. febrero de 2001;63(2):65-9.
93. Fisch IR, Frank J. Oral contraceptives and blood pressure. JAMA. 6 de junio de 1977;237(23):2499-503.
94. Mekonnen TT, Woldeyohannes SM, Yigzaw T. Contraceptive use in women with hypertension and diabetes: cross-sectional study in northwest Ethiopia. Int J Womens Health [Internet]. 11 de diciembre de 2015 [citado 27 de mayo de 2023];7:957-64. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4686315/
95. Millet D, Keledjian P, Corvol P. CONTRACEPTION PAR LA NORGESTRIENONE EN CONTINU CHEZ LES FEMMES HYPERTENDUES. EFFETS SUR LA TENSION ARTERIELLE, LES LIPIDES, LA GLYCEMIE ET L’ANGIOTENSINOGENE [Internet]. [citado 28 de mayo de 2023]. Disponible en: https://www.embase.com/records?subaction=viewrecord&id=L10153096
96. Kalenga CZ, Metcalfe A, Ahmed SB, Sharanya R, MacRae JM, Nerenberg K, et al. Abstract 031: Association Between Non-Oral Hormonal Contraceptives and Blood Pressure: A Systematic Review. Hypertension [Internet]. septiembre de 2019 [citado 14 de octubre de 2023];74(Suppl_1):A031-A031. Disponible en: https://www.ahajournals.org/doi/10.1161/hyp.74.suppl_1.031
97. Kalenga CZ, Dumanski SM, Metcalfe A, Robert M, Nerenberg KA, MacRae JM, et al. The effect of non-oral hormonal contraceptives on hypertension and blood pressure: A systematic review and meta-analysis. Physiol Rep. mayo de 2022;10(9):e15267.
98. Kovell LC, Meyerovitz CV, Skaritanov E, Ayturk D, Person SD, Kumaraswami T, et al. Hypertension and contraceptive use among women of child-bearing age in the United States from 2001 to 2018. J Hypertens. 1 de abril de 2022;40(4):776-84.
99. Leaf DA, Bland D, Schaad D, Neighbor WE, Scott CS. Oral contraceptive use and coronary risk factors in women. Am J Med Sci. junio de 1991;301(6):365-8.
100. Lidegaard O, Edström B, Kreiner S. Oral contraceptives and venous thromboembolism. A case-control study. Contraception. mayo de 1998;57(5):291-301.
101. Lidegaard Ø, Nielsen LH, Skovlund CW, Skjeldestad FE, Løkkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ. 25 de octubre de 2011;343:d6423.
102. Mann J, Vessey M, Thorogood M, Doll S. Myocardial infarction in young women with special reference to oral contraceptive practice [Internet]. [citado 14 de octubre de 2023]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/1169093/
103. Meinel H, Göretzlehner G, Heinemann L. [Hormonal contraceptives and cardiovascular risk. Results of an East German multicenter case control study]. Zentralbl Gynakol. 1988;110(23):1507-14.
104. Nessa A, Latif SA, Siddiqui NI. Risk of cardiovascular diseases with oral contraceptives. Mymensingh Med J MMJ. julio de 2006;15(2):220-4.
105. Perritt J, Fox M, Jamshidi R, Wang J, McDonald-Mosley R, Burke AE. Undesired pregnancy, contraceptive counseling and postpartum contraception use in women with medical comorbidities: An analysis of data from the maryland pregnancy risk assessment monitoring system. Contraception [Internet]. 2011;84(3):325-6. Disponible en: https://www.embase.com/search/results?subaction=viewrecord&id=L70622590&from=export
106. Wieder DR, Pattimakiel L. Examining the efficacy, safety, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing). Int J Womens Health. 12 de noviembre de 2010;2:401-9.
107. Arthes FG, Masi AT. Myocardial infarction in younger women. Associated clinical features and relationship to use of oral contraceptive drugs. Chest. noviembre de 1976;70(5):574-83.
108. Chaudhury N, Gupta AN, Hazra MN, Hingorani V, Kochhar M, Kodkany BS, et al. Phase III-clinical trial with Norplant-2 (covered rods). Report of a 24-month study. National Programme of Research in Human Reproduction. Division of Human Resource Development Research Indian Council of Medical Research Ansari Nagar, New Delhi, India. Contraception. diciembre de 1988;38(6):659-73.
109. Chen BA, Panther L, Marzinke MA, Hendrix CW, Hoesley CJ, van der Straten A, et al. Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings: A Double-Blind Randomized Trial. J Acquir Immune Defic Syndr 1999. 1 de noviembre de 2015;70(3):242-9.
110. Maino A, Siegerink B, Algra A, Peyvandi F, Rosendaal FR. Recurrence and Mortality in Young Women With Myocardial Infarction or Ischemic Stroke: Long-term Follow-up of the Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) Study. JAMA Intern Med. enero de 2016;176(1):134-6.
111. Sivin I, Stern J. Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research (ICCR). Fertil Steril. enero de 1994;61(1):70-7.
112. Ueda Y, Kamiya CA, Horiuchi C, Miyoshi T, Hazama R, Tsuritani M, et al. Safety and efficacy of a 52-mg levonorgestrel-releasing intrauterine system in women with cardiovascular disease. J Obstet Gynaecol Res. febrero de 2019;45(2):382-8.
113. Wang C, Li Y, Bai J, Qian W, Zhou J, Sun Z, et al. General and central obesity, combined oral contraceptive use and hypertension in Chinese women. Am J Hypertens. diciembre de 2011;24(12):1324-30.
114. Mant J, Painter R, Vessey M. Risk of myocardial infarction, angina and stroke in users of oral contraceptives: an updated analysis of a cohort study. Br J Obstet Gynaecol. agosto de 1998;105(8):890-6.
115. Jensen G, Nyboe J, Appleyard M, Schnohr P. Risk factors for acute myocardial infarction in Copenhagen, II: Smoking, alcohol intake, physical activity, obesity, oral contraception, diabetes, lipids, and blood pressure. Eur Heart J. marzo de 1991;12(3):298-308.
116. Dunn N, Thorogood M, Faragher B, de Caestecker L, MacDonald TM, McCollum C, et al. Oral contraceptives and myocardial infarction: results of the MICA case-control study. BMJ [Internet]. 12 de junio de 1999 [citado 27 de mayo de 2023];318(7198):1579-84. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC28136/
117. D’Avanzo B, La Vecchia C, Negri E, Parazzini F, Franceschi S. Oral contraceptive use and risk of myocardial infarction: an Italian case-control study. J Epidemiol Community Health. junio de 1994;48(3):324-5.
118. Lidegaard O. Oral contraceptives, pregnancy, and the risk of cerebral thromboembolism: the influence of diabetes, hypertension, migraine and previous thrombotic disease [Letter]. Br J Obstet Gynaecol. 1996;103:94.
119. Lidegaard Ø, Kreiner S. Contraceptives and cerebral thrombosis: a five-year national case-control study. Contraception. marzo de 2002;65(3):197-205.
120. Siritho S, Thrift AG, McNeil JJ, You RX, Davis SM, Donnan GA, et al. Risk of ischemic stroke among users of the oral contraceptive pill: The Melbourne Risk Factor Study (MERFS) Group. Stroke. julio de 2003;34(7):1575-80.
121. Nightingale A, Farmer RDT. Ischemic stroke in young women: a nested case-control study using the UK General Practice Research Database - PubMed [Internet]. 2004 [citado 28 de mayo de 2023]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/15143296/
122. Narkiewicz K, Graniero GR, D’Este D, Mattarei M, Zonzin P, Palatini P. Ambulatory blood pressure in mild hypertensive women taking oral contraceptives. A case-control study. Am J Hypertens. marzo de 1995;8(3):249-53.
123. Lubianca JN, Faccin CS, Fuchs FD. Oral contraceptives: a risk factor for uncontrolled blood pressure among hypertensive women. Contraception. enero de 2003;67(1):19-24.
124. Croft P, Hannaford PC. Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners’ oral contraception study. BMJ. 21 de enero de 1989;298(6667):165-8.
125. Hannaford PC, Croft PR, Kay CR. Oral contraception and stroke. Evidence from the Royal College of General Practitioners’ Oral Contraception Study. Stroke. mayo de 1994;25(5):935-42.
126. World Health Organization. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case control study. The Lancet. 1995;346(8).
127. World Health Organization. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception. mayo de 1998;57(5):315-24.
128. Van Den Bosch M a. a. J, Kemmeren JM, Tanis BC, Mali WPTM, Helmerhorst FM, Rosendaal FR, et al. The RATIO study: oral contraceptives and the risk of peripheral arterial disease in young women. J Thromb Haemost JTH. marzo de 2003;1(3):439-44.
129. World Health Organization. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. The Lancet [Internet]. 26 de abril de 1997 [citado 28 de mayo de 2023];349(9060):1202-9. Disponible en: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(97)02358-1/fulltext
130. Tanis BC, van den Bosch MA, Kemmeren JM, Cats VM, Helmerhorst FM, Algra A, et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med. 20 de diciembre de 2001;345(25):1787-93.
131. Collaborative Group for the Study of Stroke in Young Women. Oral Contraceptives and Stroke in Young Women: Associated Risk Factors. JAMA [Internet]. 17 de febrero de 1975 [citado 28 de mayo de 2023];231(7):718-22. Disponible en: https://doi.org/10.1001/jama.1975.03240190022010
132. World Health Organization. Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet Lond Engl. 24 de agosto de 1996;348(9026):505-10.
133. Lidegaard O. Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study. BMJ. 10 de abril de 1993;306(6883):956-63.
134. Lidegaard O. Oral contraceptives, pregnancy and the risk of cerebral thromboembolism: the influence of diabetes, hypertension, migraine and previous thrombotic disease. Br J Obstet Gynaecol. febrero de 1995;102(2):153-9.
135. World Health Organization. Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet Lond Engl. 24 de agosto de 1996;348(9026):498-505.
136. Kemmeren JM, Tanis BC, van den Bosch MAAJ, Bollen ELEM, Helmerhorst FM, van der Graaf Y, et al. Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke. Stroke. mayo de 2002;33(5):1202-8.
137. de Morais TL, Giribela C, Nisenbaum MG, Guerra G, Mello N, Baracat E, et al. Effects of a contraceptive containing drospirenone and ethinylestradiol on blood pressure, metabolic profile and neurohumoral axis in hypertensive women at reproductive age. Eur J Obstet Gynecol Reprod Biol. noviembre de 2014;182:113-7.
138. de Rossi P, Giribela CRG, Baracat EC, Colombo FMC, Melo NR. Evaluation of blood pressure, body mass index, lipid profile and insulin resistance in mild hypertensive overweight women with the use of a low dose combined oral contraceptive containing drospirenone: Results from a prospective clinical trial. G Ital Ostet E Ginecol [Internet]. 1 de enero de 2014;36:117-9. Disponible en: https://www.researchgate.net/publication/285109278_Evaluation_of_blood_pressure_body_mass_index_lipid_profile_and_insulin_resistance_in_mild_hypertensive_overweight_women_with_the_use_of_a_low_dose_combined_oral_contraceptive_containing_drospirenone_R
139. Bounhoure JP, Galinier M, Roncalli J, Assoun B, Puel J. [Myocardial infarction and oral contraceptives]. Bull Acad Natl Med. marzo de 2008;192(3):569-79; discussion 579.
140. Elkik F, Basdevant A, Jackanicz TM, Guy-Grand B, Mercier-Bodard C, Conard J, et al. Contraception in hypertensive women using a vaginal ring delivering estradiol and levonorgestrel. J Clin Endocrinol Metab. julio de 1986;63(1):29-35.
141. Asayama K, Satoh M, Kikuya M. Diurnal blood pressure changes. Hypertens Res [Internet]. septiembre de 2018 [citado 28 de octubre de 2023];41(9):669-78. Disponible en: https://www.nature.com/articles/s41440-018-0054-0
142. O’Brien E, Sheridan J, O’Malley K. DIPPERS AND NON-DIPPERS. The Lancet [Internet]. 13 de agosto de 1988 [citado 28 de octubre de 2023];332(8607):397. Disponible en: https://www.sciencedirect.com/science/article/pii/S014067368892867X
143. Higgins JPT, Li T, Deeks JJ. Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021) [Internet]. Cochrane. 2021 [citado 30 de enero de 2022]. Disponible en: https://training.cochrane.org/handbook/current/chapter-06
144. Khader YS, Rice J, John L, Abueita O. Oral contraceptives use and the risk of myocardial infarction: a meta-analysis. Contraception. julio de 2003;68(1):11-7.
145. Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives: A meta-analysis. JAMA. 5 de julio de 2000;284(1):72-8.
146. Sidney S, Siscovick DS, Petitti DB, Schwartz SM, Quesenberry CP, Psaty BM, et al. Myocardial infarction and use of low-dose oral contraceptives: a pooled analysis of 2 US studies. Circulation. 15 de septiembre de 1998;98(11):1058-63.
147. United States Preventive Services Task Force. Guide to clinical preventive services. 2nd ed. International Medical Publishing; 1996. 862 p.
148. Judging Confidence. Guidelines for Grading Evidence and Recommendations. Grades of Recommendation Assessment, Development, and Evaluation (GRADE) Working Group. 2003.
149. American College of Obstetricians and Gynecologists. Clinical Management Guidelines for Obstetrician–Gynecologists. Use of Hormonal Contraception in Women With Coexisting Medical Conditions. Obstet Gynecol. 2019;206(2):128-50.
150. Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep [Internet]. 2016 [citado 14 de febrero de 2024];65. Disponible en: https://www.cdc.gov/mmwr/volumes/65/rr/rr6503a1.htm
151. Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. abril de 2001;20(3 Suppl):21-35.
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.license.spa.fl_str_mv Atribución-NoComercial-SinDerivadas 4.0 Internacional
dc.rights.uri.spa.fl_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.accessrights.spa.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv Atribución-NoComercial-SinDerivadas 4.0 Internacional
http://creativecommons.org/licenses/by-nc-nd/4.0/
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.extent.spa.fl_str_mv xxi, 181 páginas + anexos
dc.format.mimetype.spa.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Universidad Nacional de Colombia
dc.publisher.program.spa.fl_str_mv Bogotá - Medicina - Maestría en Epidemiología Clínica
dc.publisher.faculty.spa.fl_str_mv Facultad de Medicina
dc.publisher.place.spa.fl_str_mv Bogotá, Colombia
dc.publisher.branch.spa.fl_str_mv Universidad Nacional de Colombia - Sede Bogotá
institution Universidad Nacional de Colombia
bitstream.url.fl_str_mv https://repositorio.unal.edu.co/bitstream/unal/86465/3/1024563440.anexos.pdf
https://repositorio.unal.edu.co/bitstream/unal/86465/5/1024563440.2024.pdf
https://repositorio.unal.edu.co/bitstream/unal/86465/4/license.txt
https://repositorio.unal.edu.co/bitstream/unal/86465/6/1024563440.anexos.pdf.jpg
https://repositorio.unal.edu.co/bitstream/unal/86465/7/1024563440.2024.pdf.jpg
bitstream.checksum.fl_str_mv 069e72664f9144c83fe3b72a1495dadd
27230557b8a632a95ea33604ba739c6d
eb34b1cf90b7e1103fc9dfd26be24b4a
513c32d3803c55f6f715100976554300
426625149f75fb496b370f36b0d60d03
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Institucional Universidad Nacional de Colombia
repository.mail.fl_str_mv repositorio_nal@unal.edu.co
_version_ 1814089715831275520
spelling Atribución-NoComercial-SinDerivadas 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Gaitán Duarte, Hernando01177b4c0a0b59e8b102e877d35febf5Estrada Orozco, Kelly Patriciaa821859c2bf07fd8f05f494636089380Losada Trujillo, Natalia3d452251e9616d30cadccfc42947f003Losada Trujillo, Natalia [0000-0002-8682-4072]Losada-Trujillo, NataliaLosada-Trujillo, NataliaLosada-Trujillo, Natalia2024-07-16T17:40:11Z2024-07-16T17:40:11Z2023https://repositorio.unal.edu.co/handle/unal/86465Universidad Nacional de ColombiaRepositorio Institucional Universidad Nacional de Colombiahttps://repositorio.unal.edu.co/ilustraciones, diagramas, tablasIntroducción: En los últimos años, la edad de las mujeres al momento del parto ha aumentado. La edad avanzada a su vez es un factor de riesgo para la aparición de enfermedades crónicas. Es necesario evaluar la seguridad y efectividad de los métodos anticonceptivos en mujeres con enfermedades crónicas y alto riesgo cardiovascular. Objetivo: Evaluar la seguridad y efectividad de los métodos anticonceptivos hormonales versus los métodos no hormonales o no uso de anticoncepción en las mujeres en edad reproductiva con deseo de fertilidad futura e hipertensión arterial. Métodos: Revisión sistemática de la literatura de amplio alcance. Se buscó en las bases de datos Medline, Embase, CENTRAL y LILACS, y en literatura gris, registros de experimentos clínicos (ECAS), agencias reguladoras, bases de datos de eventos adversos y postcomercialización. Se consideraron elegibles: ECAS, estudios de cohortes, casos y controles, series de casos, reportes de casos, registros de ECAS y reportes de eventos adversos. Se realizó la tamización por título y resumen, revisión del texto completo, selección de los estudios, extracción de la información y evaluación del riesgo de sesgo (ROBINS-I para cohortes), calidad metodológica (Newcastle Ottawa para cohortes y casos y controles) y aproximación crítica (Joanna Briggs Institute para series de casos), según el tipo de estudio, de manera independiente por dos revisores. Se realizó evaluación de la certeza de la evidencia de los desenlaces identificados mediante el enfoque GRADE de manera independiente. Se sintetizó la evidencia según el tipo de anticonceptivo hormonal y desenlace de manera cuantitativa (estimador de asociación, conteo de votos y metaanálisis) y cualitativa (síntesis narrativa). Resultados: La búsqueda arrojó 32.494 referencias, luego del proceso de selección se incluyeron 17 estudios. Se incluyeron estudios de casos y controles, cohortes y series de casos. Los desenlaces identificados y evaluados por tipo de anticonceptivo, fueron: a) Anticonceptivos orales combinados (ACOS): gestaciones no deseadas, eventos cardiovasculares adversos mayores (MACE), tromboembolismo venoso, empeoramiento de la condición de base, aumento de peso, alteración función renal y perfil metabólico, b) Anillo vaginal: gestaciones no deseadas, empeoramiento de la condición de base y del perfil metabólico, c) Anticonceptivo inyectable combinado, píldoras de sólo progestágeno (POP) e inyectables de sólo progestágeno: MACE y tromboembolismo venoso, d) ACOS o POP: MACE y enfermedad arterial periférica. Se observó que las mujeres hipertensas usando ACOS tenían un OR de 1,64 (IC95% 1,08-2,50) para eventos cerebrovasculares hemorrágicos (certeza de la evidencia: baja), y un OR para infarto agudo de miocardio en usuarias de ACOS o POP de 1,15 (IC95% 0,60-2,19) (certeza de la evidencia: muy baja), sin controlar posibles variables de confusión. La certeza de la evidencia de los otros desenlaces es muy baja. Conclusiones: Los estudios sugieren que los anticonceptivos orales combinados podrían aumentar el riesgo de eventos cerebrovasculares hemorrágicos en mujeres hipertensas, aunque la certeza de la evidencia es baja. Debido a la alta incertidumbre, lo ideal sería realizar experimentos clínicos pragmáticos o estudios de cohortes con análisis de inferencia causal. Por el momento, se deben continuar las recomendaciones por consenso de expertos, salvo en el caso de los ACOS y los eventos cerebrovasculares hemorrágicos, donde la evidencia sugiere un posible aumento del riesgo (Texto tomado de la fuente).Introduction: In recent years, the age at which women give birth has increased. Advanced maternal age is a risk factor for the development of chronic diseases. It is necessary to evaluate the safety and effectiveness of contraceptive methods in women with chronic diseases and high cardiovascular risk. Objective: To evaluate the safety and effectiveness of hormonal contraceptive methods versus non-hormonal methods or no contraception in women of reproductive age with a desire for future fertility and hypertension. Methods: A comprehensive systematic literature review was conducted. Searches were performed in the databases Medline, Embase, CENTRAL, and LILACS, as well as in grey literature, clinical trial registries (RCTs), regulatory agencies, adverse event databases, and post-marketing databases. Eligible studies included RCTs, cohort studies, case-control studies, case series, case reports, RCT registries, and adverse event reports. Screening was performed by title and abstract, followed by full-text review, study selection, data extraction, and risk of bias assessment (ROBINS-I for cohort studies), methodological quality (Newcastle Ottawa for cohort and case-control studies), and critical appraisal (Joanna Briggs Institute for case series), all conducted independently by two reviewers. The certainty of the evidence for identified outcomes was independently evaluated using the GRADE approach. Evidence was synthesized by type of hormonal contraceptive and outcome both quantitatively (association estimator, vote counting, and meta-analysis) and qualitatively (narrative synthesis). Results: The search yielded 32,494 references, and 17 studies were included after the selection process. Included studies were case-control, cohort, and case series studies. The outcomes identified and evaluated by contraceptive type were: a) Combined oral contraceptives (COCs): unintended pregnancies, major adverse cardiovascular events (MACE), venous thromboembolism, worsening of the underlying condition, weight gain, alteration of renal function and metabolic profile. b) Vaginal ring: unintended pregnancies, worsening of the underlying condition and metabolic profile. c) Combined injectable contraceptives, progestogen-only pills (POPs), and progestogen-only injectables: MACE and venous thromboembolism. d) COCs or POPs: MACE and peripheral arterial disease. It was observed that hypertensive women using COCs had an OR of 1.64 (95% CI 1.08-2.50) for hemorrhagic cerebrovascular events (certainty of the evidence: low), and an OR for acute myocardial infarction in users of COCs or POPs of 1.15 (95% CI 0.60-2.19) (certainty of the evidence: very low), without controlling for possible confounding variables. The certainty of the evidence for other outcomes is very low. Conclusions: The studies suggest that combined oral contraceptives may increase the risk of hemorrhagic cerebrovascular events in hypertensive women, although the certainty of the evidence is low. Due to the high uncertainty, pragmatic clinical trials or cohort studies with causal inference analysis are ideal. In the meantime, expert consensus recommendations should continue to be followed, except for the case of COCs and hemorrhagic cerebrovascular events, where the evidence suggests a possible increased risk.MaestríaMagister en Epidemiología ClínicaMétodos: Revisión sistemática de la literatura de amplio alcance. Se buscó en las bases de datos Medline, Embase, CENTRAL y LILACS, y en literatura gris, registros de experimentos clínicos (ECAS), agencias reguladoras, bases de datos de eventos adversos y postcomercialización. Se consideraron elegibles: ECAS, estudios de cohortes, casos y controles, series de casos, reportes de casos, registros de ECAS y reportes de eventos adversos. Se realizó la tamización por título y resumen, revisión del texto completo, selección de los estudios, extracción de la información y evaluación del riesgo de sesgo (ROBINS-I para cohortes), calidad metodológica (Newcastle Ottawa para cohortes y casos y controles) y aproximación crítica (Joanna Briggs Institute para series de casos), según el tipo de estudio, de manera independiente por dos revisores. Se realizó evaluación de la certeza de la evidencia de los desenlaces identificados mediante el enfoque GRADE de manera independiente. Se sintetizó la evidencia según el tipo de anticonceptivo hormonal y desenlace de manera cuantitativa (estimador de asociación, conteo de votos y metaanálisis) y cualitativa (síntesis narrativa).xxi, 181 páginas + anexosapplication/pdfspaUniversidad Nacional de ColombiaBogotá - Medicina - Maestría en Epidemiología ClínicaFacultad de MedicinaBogotá, ColombiaUniversidad Nacional de Colombia - Sede Bogotá100 - Filosofía y Psicología::107 - Educación, investigación, temas relacionados500 - Ciencias naturales y matemáticas::507 - Educación, investigación, temas relacionados610 - Medicina y salud::616 - Enfermedades610 - Medicina y salud::618 - Ginecología, obstetricia, pediatría, geriatría610 - Medicina y salud::613 - Salud y seguridad personal610 - Medicina y salud::615 - Farmacología y terapéutica600 - Tecnología (Ciencias aplicadas)::607 - Educación, investigación, temas relacionadosAnticonceptivos FemeninosAnticoncepción HormonalFactores de Riesgo de Enfermedad CardiacaContraceptive Agents, FemaleHormonal ContraceptionHeart Disease Risk FactorsHipertensión arterialAnticoncepción hormonalSeguridadEfectividadHypertensionHormonal contraceptionSafetyEffectivenessRevisión sistemática de amplio alcance: Seguridad y efectividad de los métodos de anticoncepción hormonal versus métodos de anticoncepción no hormonal o no uso de métodos de anticoncepción para mujeres en edad reproductiva con deseo de fertilidad futura y alto riesgo cardiovascularSystematic review of broad scope: Safety and effectiveness of hormonal contraception methods versus non-hormonal contraception methods or non-use of contraception methods for women of reproductive age with desire for future fertility and high cardiovascular riskTrabajo de grado - Maestríainfo:eu-repo/semantics/masterThesisinfo:eu-repo/semantics/acceptedVersionTexthttp://purl.org/redcol/resource_type/TM1. Grupo Banco Mundial BIRF- AIF [Internet]. [citado 7 de octubre de 2023]. Banco Mundial: Esperanza de vida al nacer. Disponible en: https://data.worldbank.org2. Wang H, Naghavi M, Allen C, Barber RM, Carter A, Casey DC, et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet [Internet]. octubre de 2016;388(10053):1459-544. Disponible en: http://www.thelancet.com/article/S0140673616310121/fulltext3. Mathews TJ, Hamilton BE. First births to older women continue to rise. NCHS data brief, no 152. [Internet]. National Center for Health Statistics. 2014 [citado 14 de enero de 2022]. Disponible en: https://www.cdc.gov/nchs/products/databriefs/db152.htm4. Organización para la Cooperación y el Desarrollo Económicos. Age of mothers at childbirth and age-specific fertility. OECD [Internet]. 2021; Disponible en: https://doi.org/10.25318/1310041801-eng5. Organization WH. Global Health Estimates 2016: Deaths by Cause, Age, Sex, by Country and by Region, 2000–2016. En: World Health Organization. Geneva; 2016.6. Global burden of disease U of W. Data Visualizations Institute for Health Metrics and Evaluation [Internet]. 2021 [citado 6 de diciembre de 2021]. Disponible en: http://www.healthdata.org/results/data-visualizations7. Hui L. Assessment of the role of ageing and non-ageing factors in death from non-communicable diseases based on a cumulative frequency model. Sci Rep 2017 71 [Internet]. agosto de 2017;7(1):1-7. Disponible en: https://www.nature.com/articles/s41598-017-08539-08. International Federation of Gynecology and Obstetrics (FIGO). Pregnancy: Risks and Complications, Figo [Internet]. 2021 [citado 28 de diciembre de 2021]. Disponible en: https://www.figo.org/pregnancy-risks-and-complications9. Parikh NI, Gonzalez JM, Anderson CAM, Judd SE, Rexrode KM, Hlatky MA, et al. Adverse Pregnancy Outcomes and Cardiovascular Disease Risk: Unique Opportunities for Cardiovascular Disease Prevention in Women: A Scientific Statement From the American Heart Association. Circulation [Internet]. 2021;143:E902-16. Disponible en: https://www.ahajournals.org/doi/abs/10.1161/CIR.000000000000096110. World Health Organization. Cardiovascular diseases (CVDs) [Internet]. 2021 [citado 6 de diciembre de 2021]. Disponible en: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)11. Centers for Disease Control and Prevention (CDC). Cardiovascular Diseases [Internet]. Division of Global Health Protection. 2021 [citado 6 de diciembre de 2021]. Disponible en: https://www.cdc.gov/globalhealth/healthprotection/ncd/cardiovascular-diseases.html12. Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscalzo J. Harrison Principios de medicina interna. 19.a ed. Graw M, editor. United States of America; 2016. 467–2770 p.13. Organisation for economic co-operation and development. OECD.Stat. [citado 7 de octubre de 2023]. Organisation for economic co-operation and development: Family Database. Disponible en: https://stats.oecd.org/Index.aspx?DataSetCode=FAMILY14. Pan American Health Organization, World Health Organization. Noncommunicable Diseases - PAHO/WHO [Internet]. 2021 [citado 6 de diciembre de 2021]. Disponible en: https://www.paho.org/en/topics/noncommunicable-diseases15. World Health Organization. Noncommunicable diseases [Internet]. Noncommunicable disease. 2021 [citado 6 de diciembre de 2021]. Disponible en: https://www.who.int/health-topics/noncommunicable-diseases#tab=tab_116. Division of Reproductive Health NC for CDP, Promotion H, Centers for Disease Control and Prevention. Unintended Pregnancy, Reproductive Health [Internet]. CDC. 2021 [citado 15 de enero de 2022]. Disponible en: https://www.cdc.gov/reproductivehealth/contraception/unintendedpregnancy/index.htm17. World Health Organization. Contraception [Internet]. World Health Organization. 2022 [citado 15 de enero de 2022]. Disponible en: https://www.who.int/health-topics/contraception#tab=tab_118. United Nations Department of Economic and Social Affairs PD. World Family Planning 2020 Highlights: Accelerating action to ensure universal access to family planning (ST/ESA/SER.A/450) [Internet]. United Nations, Department of Economic and Social Affairs, editores. United Nations. 2020. Disponible en: https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/files/documents/2020/Sep/unpd_2020_worldfamilyplanning_highlights.pdf/19. World Health Organization. Women of reproductive age (15-49 years) population (thousands) [Internet]. The global health observatory. 2021 [citado 6 de diciembre de 2021]. Disponible en: https://www.who.int/data/gho/indicator-metadata-registry/imr-details/women-of-reproductive-age-(15-49-years)-population-(thousands)20. World Health Organization. Reproductive Health indicators Guidelines for their generation, interpretation and analysis for global monitoring. WHO Library Cataloguing-in-Publication Data, editor. Vol. 1, World Health Organization. Geneva: World Health Organization; 2006. 1–69 p.21. United Nations, Department of Economic and Social Affairs. Contraceptive Use by Method 2019 Data Booklet. U N [Internet]. 2019; Disponible en: https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/files/documents/2020/Jan/un_2019_contraceptiveusebymethod_databooklet.pdf22. Ministerio de salud, Profamilia. Encuesta Nacional de Demografía y Salud 2015, Componente de salud sexual y salud reproductiva [Internet]. 1.a ed. Vol. 2. Bogotá; 2015. Disponible en: https://profamilia.org.co/wp-content/uploads/2019/05/ENDS-2015-TOMO-II.pdf23. Curtis KM, Chrisman CE, Peterson HB, WHO Programme for Mapping Best Practices in Reproductive Health. Contraception for women in selected circumstances. Obstet Gynecol. junio de 2002;99(6):1100-12.24. Curtis KM, Mohllajee AP, Martins SL, Peterson HB. Combined oral contraceptive use among women with hypertension: A systematic review. Contraception. 2006;73(2):179-88.25. Organization WH. Noncommunicable diseases country profiles 2018 [Internet]. World Health Organization. 2018 [citado 6 de diciembre de 2021]. Disponible en: https://apps.who.int/iris/handle/10665/27451226. World Health Organization. Total NCD mortality rate (per 100 000 population) , age-standardized [Internet]. The global health observatory. 2021 [citado 6 de diciembre de 2021]. Disponible en: https://www.who.int/data/gho/data/indicators/indicator-details/gho/gho-ghe-ncd-mortality-rate27. Bosco E, Hsueh L, McConeghy KW, Gravenstein S, Saade E. Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review. BMC Med Res Methodol 2021 211 [Internet]. noviembre de 2021;21(1):1-18. Disponible en: https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/s12874-021-01440-528. Medicines Agency E. Reflection paper on assessment of cardiovascular safety profile of medicinal products. Comm Med Prod Hum Use CHMP [Internet]. 2016; Disponible en: https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-assessment-cardiovascular-safety-profile-medicinal-products_en.pdf29. Food and Drug Administration (FDA). FDA Background Document Endocrinologic and Metabolic Drugs Advisory Committee Meeting. FDA [Internet]. 2018; Disponible en: https://www.fda.gov/media/121272/download30. Petitti DB, Sidney S, Quesenberry CP, Bernstein A. Incidence of stroke and myocardial infarction in women of reproductive age. Stroke [Internet]. 1997;28(2):280-3. Disponible en: https://www.ahajournals.org/doi/abs/10.1161/01.str.28.2.28031. Centers for Disease Control and Prevention. NHANES - National Health and Nutrition Examination Survey 2013–2016 [Internet]. Unpublished National Heart, Lung Unpublished National Heart, Lung, and Blood Institute. 2016 [citado 18 de enero de 2022]. Disponible en: https://www.cdc.gov/nchs/nhanes/index.htm32. Chopra H, Nanda N, Narula J, Wander G. Hypertension: New Frontiers: A Textbook of Cardiology [Internet]. Jaypee. 2021 [citado 6 de diciembre de 2021]. p. 1. Disponible en: https://books.google.com.co/books?id=_gFBEAAAQBAJ&pg=PR31&lpg=PR31&dq=CVD+MACE+MAKE&source=bl&ots=gp5j_j5qyn&sig=ACfU3U0NpXDhtlIx3aL34DDNysTtWaydUw&hl=es&sa=X&ved=2ahUKEwi39Oz6t870AhWaVzABHQYrDT8Q6AF6BAgQEAM#v=onepage&q=CVD MACE MAKE&f=false33. Beevers G, Lip GYH, O’brien E. ABC of hypertension: The pathophysiology of hypertension. Br Med J [Internet]. abril de 2001;322(7291):912. Disponible en: /pmc/articles/PMC1120075/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1120075/34. Stergiou GS, Palatini P, Parati G, O’Brien E, Januszewicz A, Lurbe E, et al. 2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. J Hypertens [Internet]. julio de 2021;39(7):1293-302. Disponible en: https://journals.lww.com/jhypertension/Fulltext/2021/07000/2021_European_Society_of_Hypertension_practice.5.aspx35. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension [Internet]. junio de 2020;75(6):1334-57. Disponible en: http://ahajournals.org36. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J [Internet]. septiembre de 2018;39(33):3021-104. Disponible en: https://academic.oup.com/eurheartj/article/39/33/3021/507911937. National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management, NICE guideline [Internet]. NICE. 2019 [citado 20 de diciembre de 2021]. Disponible en: https://www.nice.org.uk/guidance/ng136/chapter/Recommendations#diagnosing-hypertension38. Ostchega Y, Fryar CD, Nwankwo T, Nguyen DT. Hypertension Prevalence Among Adults Aged 18 and Over: United States, 2017-2018 Key findings Data from the National Health and Nutrition Examination Survey. Natl Cent Health Stat [Internet]. 2017; Disponible en: https://www.cdc.gov/nchs/products/databriefs/db364.htm39. Luo D, Cheng Y, Zhang H, Ba M, Chen P, Li H, et al. Association between high blood pressure and long term cardiovascular events in young adults: Systematic review and meta-analysis. The BMJ. 2020;370.40. Mockus Sivickas I, Trujillo Güiza ML. Obesidad y enfermedades asociadas. Universida. Universidad Nacional de Colombia, editor. Bogotá D.C., Colombia: Universidad Nacional de Colombia; 2013. 1–206 p.41. World Health Organization. Global action plan for the prevention and control of noncommunicable diseases 2013-2020. World Health Organ [Internet]. 2013;102. Disponible en: http://apps.who.int/iris/bitstream/10665/94384/1/9789241506236_eng.pdf42. World Health Organization. Medical eligibility criteria for contraceptive use. 5.a ed. WHO Library Cataloguing-in-Publication Data, editor. Geneva: World Health Organization; 2015. 1–276 p.43. Quarini CA. History of contraception. Womens Health Med [Internet]. septiembre de 2005;2(5):28-30. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S174418700600087444. World Health Organization Department of Reproductive Health and Research (WHO/RHR), Johns Hopkins Bloomberg School of Public Health/Center for Communication Program. Family Planning: A Global Handbook for Providers [Internet]. Baltimore and Geneva; 2022. 1–460 p. Disponible en: https://fphandbook.org/sites/default/files/WHO-JHU-FPHandbook-2022Ed-v221114b.pdf45. Organización Mundial de la Salud. Planificación familiar [Internet]. Organización Mundial de la Salud. 2020 [citado 21 de enero de 2022]. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/family-planning-contraception46. Profamilia. Profamilia. [citado 11 de octubre de 2023]. Anticonceptivos orales. Disponible en: https://profamilia.org.co/productos/anticonceptivos-orales/47. World Health Organization. World Health Organization. [citado 9 de octubre de 2023]. Family planning/contraception methods. Disponible en: https://www.who.int/news-room/fact-sheets/detail/family-planning-contraception48. Centers for Disease Control and Prevention. CDC. 2023 [citado 9 de octubre de 2023]. Contraception. Disponible en: https://www.cdc.gov/reproductivehealth/contraception/index.htm49. Bergendal A, Persson I, Odeberg J, Sundström A, Holmström M, Schulman S, et al. Association of venous thromboembolism with hormonal contraception and thrombophilic genotypes. Obstet Gynecol. septiembre de 2014;124(3):600-9.50. Dinger J, Assmann A, Möhner S, Minh TD. Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study. J Fam Plann Reprod Health Care. julio de 2010;36(3):123-9.51. Farmer RD, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet Lond Engl. 11 de enero de 1997;349(9045):83-8.52. Vademecum. Implanon NXT Implante 68 mg [Internet]. 2020 [citado 8 de diciembre de 2021]. Disponible en: https://www.vademecum.es/equivalencia-lista-implanon+nxt-colombia-g03ac08-19002715-co_153. Vademecum. Jadelle Implante 75 mg [Internet]. 2015 [citado 8 de diciembre de 2021]. Disponible en: https://www.vademecum.es/equivalencia-lista-jadelle+implante+75+mg-colombia-g03ac03-19002680-co_154. Vademecum. Norplant ii implant 75 mg [Internet]. 2015 [citado 8 de diciembre de 2021]. Disponible en: https://www.vademecum.es/equivalencia-lista-norplant+ii+implant+75+mg--g03ac03--_155. Profamilia. Profamilia. [citado 7 de octubre de 2023]. Píldoras anticonceptivas de emergencia. Disponible en: https://profamilia.org.co/productos/anticonceptivos-de-emergencia/56. Vademecum. Mirena Sistema de liberación intrauterino 20 µg/24 h de Colombia [Internet]. 2018 [citado 7 de diciembre de 2021]. Disponible en: https://www.vademecum.es/equivalencia-lista-mirena+sistema+de+liberacion+intrauterino+20+µg%2F24+h-colombia-g02ba03-19002682-co_157. Hassoun D. Méthodes de contraception naturelle et méthodes barrières. RPC contraception CNGOF. Gynécologie Obstétrique Fertil Sénologie. diciembre de 2018;46(12):873-82.58. Brabaharan S, Veettil SK, Kaiser JE, Raja Rao VR, Wattanayingcharoenchai R, Maharajan M, et al. Association of Hormonal Contraceptive Use With Adverse Health Outcomes. JAMA Netw Open [Internet]. enero de 2022;5(1):e2143730. Disponible en: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/278811959. Lidegaard Ø, Edström B, Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception [Internet]. 1 de marzo de 2002 [citado 7 de octubre de 2023];65(3):187-96. Disponible en: https://www.sciencedirect.com/science/article/pii/S001078240100307960. Heinemann LA, Lewis MA, Spitzer WO, Thorogood M, Guggenmoos-Holzmann I, Bruppacher R. Thromboembolic stroke in young women. A European case-control study on oral contraceptives. Transnational Research Group on Oral Contraceptives and the Health of Young Women. Contraception. enero de 1998;57(1):29-37.61. Lewis MA, Heinemann LAJ, Spitzer WO, MacRae KD, Bruppacher R. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women: Results from the transnational study on oral contraceptives and the health of young women. Contraception [Internet]. 1 de septiembre de 1997 [citado 7 de octubre de 2023];56(3):129-40. Disponible en: https://www.sciencedirect.com/science/article/pii/S001078249700118262. Beller FK, Ebert C. Effects of oral contraceptives on blood coagulation. A review. Obstet Gynecol Surv. julio de 1985;40(7):425-36.63. Notelovitz M. Oral contraception and coagulation. Clin Obstet Gynecol. marzo de 1985;28(1):73-83.64. Bonnar J. Coagulation effects of oral contraception. Am J Obstet Gynecol. octubre de 1987;157(4 Pt 2):1042-8.65. Jakes A, Coad F, Nelson-Piercy C. A review of contraceptive methods for women with cardiac disease. Obstet Gynaecol. 28 de enero de 2018;20:21-9.66. Cilia La Corte AL, Carter AM, Turner AJ, Grant PJ, Hooper NM. The bradykinin-degrading aminopeptidase P is increased in women taking the oral contraceptive pill. J Renin-Angiotensin-Aldosterone Syst JRAAS. diciembre de 2008;9(4):221-5.67. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Establishing Effectiveness and Safety for Hormonal Drug Products Intended to Prevent Pregnancy Guidance for Industry. Clinical/Medical [Internet]. 2019;1-9. Disponible en: https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm68. Harvard: School of Public Health. Obesity Prevention Source. 2012 [citado 7 de octubre de 2023]. Measuring Obesity. Disponible en: https://www.hsph.harvard.edu/obesity-prevention-source/obesity-definition/how-to-measure-body-fatness/69. Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol [Internet]. enero de 2017;112(1):18-35. Disponible en: https://journals.lww.com/ajg/Fulltext/2017/01000/ACG_Clinical_Guideline__Evaluation_of_Abnormal.13.aspx70. Pagana K, Pagana T, Pagana T. Mosby’s® Diagnostic and Laboratory Test Reference. 15.a ed. Elsevier, editor. United States of America: Elsevier; 2020. 1095 p.71. Mourad O, Hossam H, Zbys F, Ahmed E. Rayyan — a web and mobile app for systematic reviews [Internet]. 2016. (Systematic Reviews). Disponible en: DOI: 10.1186/s13643-016-0384-472. REDCap [Internet]. [citado 18 de octubre de 2023]. Disponible en: https://www.project-redcap.org/73. Collaboration TC. Review Manager (RevMan) [Internet]. 2020. Disponible en: https://training.cochrane.org/online-learning/core-software-cochrane-reviews/revman/revman-5-download/download-and-installation74. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ [Internet]. octubre de 2016;355. Disponible en: https://www.bmj.com/content/355/bmj.i4919 https://www.bmj.com/content/355/bmj.i4919.abstract75. Wells G, Shea B, O’Connell D, Peterson J, Welch V. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis [Internet]. The Ottawa Hospital. 2011 [citado 15 de marzo de 2022]. Disponible en: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp76. Munn Z, Barker T, Moola S, Tufanaru C, Stern C, McArthur A, et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evidence Synthesis. 2020;18(10):2127-33.77. Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, et al. Chapter 7: Systematic reviews of etiology and risk. JBI Evidence Synthesis [Internet]. 2020; Disponible en: https://jbi.global/critical-appraisal-tools78. Deeks JJ, Higgins JPT, Altman DG. Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021) [Internet]. Cochrane. 2021 [citado 30 de enero de 2022]. Disponible en: https://training.cochrane.org/handbook/current/chapter-10#section-10-1079. Stata. Stata 15 [Internet]. Stata. 2017 [citado 15 de marzo de 2022]. Disponible en: https://www.stata.com/stata15/80. Kevin M S, Andrew G D. EpiInformatics.com. [citado 17 de octubre de 2023]. OpenEpi: Open Source Epidemiologic Statistics for Public Health. Disponible en: https://www.openepi.com/TwobyTwo/TwobyTwo.htm81. McKenzie JE, Brennan SE, Ryan RE, Thomson HJ, Johnston RV. Chapter 9: Summarizing study characteristics and preparing for synthesis. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021) [Internet]. Cochrane. 2021 [citado 30 de enero de 2022]. Disponible en: https://training.cochrane.org/handbook/current/chapter-0982. Schünemann H, Brozek J, Guyatt G, Oxman A. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) [Internet]. Grading of Recommendations, Assessment, Development and Evaluation (GRADE) Working Group. GRADE; 2013. Disponible en: https://gdt.gradepro.org/app/handbook/handbook.html83. University M. GRADEpro GDT [Internet]. Hamilton (ON): McMaster University (developed by Evidence Prime); Disponible en: gradepro.org84. Ministerio de salud y protección social. Resolución 8430 de 1993 del Ministerio de Salud. 1993. p. 19.85. Adler TE, Usselman CW, Takamata A, Stachenfeld NS. Blood pressure predicts endothelial function and the effects of ethinyl estradiol exposure in young women. Am J Physiol Heart Circ Physiol. 1 de octubre de 2018;315(4):H925-33.86. Ananijevic-Pandey J, Vlajinac H. Myocardial Infarction in Young Women with Reference to Oral Contraceptive Use. International Journal of Epidemiology. 1989;4.87. Andrews J. Hormonal contraceptives with ethinyl estradiol were associated with increased thrombotic stroke and MI. ACP Journal Club. 2012;157(8).88. Correia P, Machado S, Eskandari A, Michel P. Ischemic stroke in women using contraceptives: Causes, characteristics and outcome. Int J Stroke [Internet]. octubre de 2016 [citado 27 de mayo de 2023];11(3_suppl):4-288. Disponible en: http://journals.sagepub.com/doi/10.1177/174749301667056789. Dinger J, Assmann A, Moehner S. Long-term active surveillance study for oral contraceptives (LASS): Impact of oral contraceptive use on the start of antihypertensive treatment. Pharmacoepidemiol Drug Saf. 2010;19:S232.90. Alcalde Dominguez A, Rabasa Antonijuan J, Cusidó Gimferrer M, Ortuño MJ. Therapy with Ulipristal Acetate in a Hypertensive Patient. Case Rep Med. 2018;2018:1091520.91. Dong W, Colhoun HM, Poulter NR. Blood pressure in women using oral contraceptives: results from the Health Survey for England 1994. J Hypertens. octubre de 1997;15(10):1063-8.92. Dunn NR, Arscott A, Thorogood M. The relationship between use of oral contraceptives and myocardial infarction in young women with fatal outcome, compared to those who survive: results from the MICA case-control study. Contraception. febrero de 2001;63(2):65-9.93. Fisch IR, Frank J. Oral contraceptives and blood pressure. JAMA. 6 de junio de 1977;237(23):2499-503.94. Mekonnen TT, Woldeyohannes SM, Yigzaw T. Contraceptive use in women with hypertension and diabetes: cross-sectional study in northwest Ethiopia. Int J Womens Health [Internet]. 11 de diciembre de 2015 [citado 27 de mayo de 2023];7:957-64. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4686315/95. Millet D, Keledjian P, Corvol P. CONTRACEPTION PAR LA NORGESTRIENONE EN CONTINU CHEZ LES FEMMES HYPERTENDUES. EFFETS SUR LA TENSION ARTERIELLE, LES LIPIDES, LA GLYCEMIE ET L’ANGIOTENSINOGENE [Internet]. [citado 28 de mayo de 2023]. Disponible en: https://www.embase.com/records?subaction=viewrecord&id=L1015309696. Kalenga CZ, Metcalfe A, Ahmed SB, Sharanya R, MacRae JM, Nerenberg K, et al. Abstract 031: Association Between Non-Oral Hormonal Contraceptives and Blood Pressure: A Systematic Review. Hypertension [Internet]. septiembre de 2019 [citado 14 de octubre de 2023];74(Suppl_1):A031-A031. Disponible en: https://www.ahajournals.org/doi/10.1161/hyp.74.suppl_1.03197. Kalenga CZ, Dumanski SM, Metcalfe A, Robert M, Nerenberg KA, MacRae JM, et al. The effect of non-oral hormonal contraceptives on hypertension and blood pressure: A systematic review and meta-analysis. Physiol Rep. mayo de 2022;10(9):e15267.98. Kovell LC, Meyerovitz CV, Skaritanov E, Ayturk D, Person SD, Kumaraswami T, et al. Hypertension and contraceptive use among women of child-bearing age in the United States from 2001 to 2018. J Hypertens. 1 de abril de 2022;40(4):776-84.99. Leaf DA, Bland D, Schaad D, Neighbor WE, Scott CS. Oral contraceptive use and coronary risk factors in women. Am J Med Sci. junio de 1991;301(6):365-8.100. Lidegaard O, Edström B, Kreiner S. Oral contraceptives and venous thromboembolism. A case-control study. Contraception. mayo de 1998;57(5):291-301.101. Lidegaard Ø, Nielsen LH, Skovlund CW, Skjeldestad FE, Løkkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ. 25 de octubre de 2011;343:d6423.102. Mann J, Vessey M, Thorogood M, Doll S. Myocardial infarction in young women with special reference to oral contraceptive practice [Internet]. [citado 14 de octubre de 2023]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/1169093/103. Meinel H, Göretzlehner G, Heinemann L. [Hormonal contraceptives and cardiovascular risk. Results of an East German multicenter case control study]. Zentralbl Gynakol. 1988;110(23):1507-14.104. Nessa A, Latif SA, Siddiqui NI. Risk of cardiovascular diseases with oral contraceptives. Mymensingh Med J MMJ. julio de 2006;15(2):220-4.105. Perritt J, Fox M, Jamshidi R, Wang J, McDonald-Mosley R, Burke AE. Undesired pregnancy, contraceptive counseling and postpartum contraception use in women with medical comorbidities: An analysis of data from the maryland pregnancy risk assessment monitoring system. Contraception [Internet]. 2011;84(3):325-6. Disponible en: https://www.embase.com/search/results?subaction=viewrecord&id=L70622590&from=export106. Wieder DR, Pattimakiel L. Examining the efficacy, safety, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing). Int J Womens Health. 12 de noviembre de 2010;2:401-9.107. Arthes FG, Masi AT. Myocardial infarction in younger women. Associated clinical features and relationship to use of oral contraceptive drugs. Chest. noviembre de 1976;70(5):574-83.108. Chaudhury N, Gupta AN, Hazra MN, Hingorani V, Kochhar M, Kodkany BS, et al. Phase III-clinical trial with Norplant-2 (covered rods). Report of a 24-month study. National Programme of Research in Human Reproduction. Division of Human Resource Development Research Indian Council of Medical Research Ansari Nagar, New Delhi, India. Contraception. diciembre de 1988;38(6):659-73.109. Chen BA, Panther L, Marzinke MA, Hendrix CW, Hoesley CJ, van der Straten A, et al. Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings: A Double-Blind Randomized Trial. J Acquir Immune Defic Syndr 1999. 1 de noviembre de 2015;70(3):242-9.110. Maino A, Siegerink B, Algra A, Peyvandi F, Rosendaal FR. Recurrence and Mortality in Young Women With Myocardial Infarction or Ischemic Stroke: Long-term Follow-up of the Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) Study. JAMA Intern Med. enero de 2016;176(1):134-6.111. Sivin I, Stern J. Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research (ICCR). Fertil Steril. enero de 1994;61(1):70-7.112. Ueda Y, Kamiya CA, Horiuchi C, Miyoshi T, Hazama R, Tsuritani M, et al. Safety and efficacy of a 52-mg levonorgestrel-releasing intrauterine system in women with cardiovascular disease. J Obstet Gynaecol Res. febrero de 2019;45(2):382-8.113. Wang C, Li Y, Bai J, Qian W, Zhou J, Sun Z, et al. General and central obesity, combined oral contraceptive use and hypertension in Chinese women. Am J Hypertens. diciembre de 2011;24(12):1324-30.114. Mant J, Painter R, Vessey M. Risk of myocardial infarction, angina and stroke in users of oral contraceptives: an updated analysis of a cohort study. Br J Obstet Gynaecol. agosto de 1998;105(8):890-6.115. Jensen G, Nyboe J, Appleyard M, Schnohr P. Risk factors for acute myocardial infarction in Copenhagen, II: Smoking, alcohol intake, physical activity, obesity, oral contraception, diabetes, lipids, and blood pressure. Eur Heart J. marzo de 1991;12(3):298-308.116. Dunn N, Thorogood M, Faragher B, de Caestecker L, MacDonald TM, McCollum C, et al. Oral contraceptives and myocardial infarction: results of the MICA case-control study. BMJ [Internet]. 12 de junio de 1999 [citado 27 de mayo de 2023];318(7198):1579-84. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC28136/117. D’Avanzo B, La Vecchia C, Negri E, Parazzini F, Franceschi S. Oral contraceptive use and risk of myocardial infarction: an Italian case-control study. J Epidemiol Community Health. junio de 1994;48(3):324-5.118. Lidegaard O. Oral contraceptives, pregnancy, and the risk of cerebral thromboembolism: the influence of diabetes, hypertension, migraine and previous thrombotic disease [Letter]. Br J Obstet Gynaecol. 1996;103:94.119. Lidegaard Ø, Kreiner S. Contraceptives and cerebral thrombosis: a five-year national case-control study. Contraception. marzo de 2002;65(3):197-205.120. Siritho S, Thrift AG, McNeil JJ, You RX, Davis SM, Donnan GA, et al. Risk of ischemic stroke among users of the oral contraceptive pill: The Melbourne Risk Factor Study (MERFS) Group. Stroke. julio de 2003;34(7):1575-80.121. Nightingale A, Farmer RDT. Ischemic stroke in young women: a nested case-control study using the UK General Practice Research Database - PubMed [Internet]. 2004 [citado 28 de mayo de 2023]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/15143296/122. Narkiewicz K, Graniero GR, D’Este D, Mattarei M, Zonzin P, Palatini P. Ambulatory blood pressure in mild hypertensive women taking oral contraceptives. A case-control study. Am J Hypertens. marzo de 1995;8(3):249-53.123. Lubianca JN, Faccin CS, Fuchs FD. Oral contraceptives: a risk factor for uncontrolled blood pressure among hypertensive women. Contraception. enero de 2003;67(1):19-24.124. Croft P, Hannaford PC. Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners’ oral contraception study. BMJ. 21 de enero de 1989;298(6667):165-8.125. Hannaford PC, Croft PR, Kay CR. Oral contraception and stroke. Evidence from the Royal College of General Practitioners’ Oral Contraception Study. Stroke. mayo de 1994;25(5):935-42.126. World Health Organization. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case control study. The Lancet. 1995;346(8).127. World Health Organization. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception. mayo de 1998;57(5):315-24.128. Van Den Bosch M a. a. J, Kemmeren JM, Tanis BC, Mali WPTM, Helmerhorst FM, Rosendaal FR, et al. The RATIO study: oral contraceptives and the risk of peripheral arterial disease in young women. J Thromb Haemost JTH. marzo de 2003;1(3):439-44.129. World Health Organization. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. The Lancet [Internet]. 26 de abril de 1997 [citado 28 de mayo de 2023];349(9060):1202-9. Disponible en: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(97)02358-1/fulltext130. Tanis BC, van den Bosch MA, Kemmeren JM, Cats VM, Helmerhorst FM, Algra A, et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med. 20 de diciembre de 2001;345(25):1787-93.131. Collaborative Group for the Study of Stroke in Young Women. Oral Contraceptives and Stroke in Young Women: Associated Risk Factors. JAMA [Internet]. 17 de febrero de 1975 [citado 28 de mayo de 2023];231(7):718-22. Disponible en: https://doi.org/10.1001/jama.1975.03240190022010132. World Health Organization. Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet Lond Engl. 24 de agosto de 1996;348(9026):505-10.133. Lidegaard O. Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study. BMJ. 10 de abril de 1993;306(6883):956-63.134. Lidegaard O. Oral contraceptives, pregnancy and the risk of cerebral thromboembolism: the influence of diabetes, hypertension, migraine and previous thrombotic disease. Br J Obstet Gynaecol. febrero de 1995;102(2):153-9.135. World Health Organization. Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet Lond Engl. 24 de agosto de 1996;348(9026):498-505.136. Kemmeren JM, Tanis BC, van den Bosch MAAJ, Bollen ELEM, Helmerhorst FM, van der Graaf Y, et al. Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke. Stroke. mayo de 2002;33(5):1202-8.137. de Morais TL, Giribela C, Nisenbaum MG, Guerra G, Mello N, Baracat E, et al. Effects of a contraceptive containing drospirenone and ethinylestradiol on blood pressure, metabolic profile and neurohumoral axis in hypertensive women at reproductive age. Eur J Obstet Gynecol Reprod Biol. noviembre de 2014;182:113-7.138. de Rossi P, Giribela CRG, Baracat EC, Colombo FMC, Melo NR. Evaluation of blood pressure, body mass index, lipid profile and insulin resistance in mild hypertensive overweight women with the use of a low dose combined oral contraceptive containing drospirenone: Results from a prospective clinical trial. G Ital Ostet E Ginecol [Internet]. 1 de enero de 2014;36:117-9. Disponible en: https://www.researchgate.net/publication/285109278_Evaluation_of_blood_pressure_body_mass_index_lipid_profile_and_insulin_resistance_in_mild_hypertensive_overweight_women_with_the_use_of_a_low_dose_combined_oral_contraceptive_containing_drospirenone_R139. Bounhoure JP, Galinier M, Roncalli J, Assoun B, Puel J. [Myocardial infarction and oral contraceptives]. Bull Acad Natl Med. marzo de 2008;192(3):569-79; discussion 579.140. Elkik F, Basdevant A, Jackanicz TM, Guy-Grand B, Mercier-Bodard C, Conard J, et al. Contraception in hypertensive women using a vaginal ring delivering estradiol and levonorgestrel. J Clin Endocrinol Metab. julio de 1986;63(1):29-35.141. Asayama K, Satoh M, Kikuya M. Diurnal blood pressure changes. Hypertens Res [Internet]. septiembre de 2018 [citado 28 de octubre de 2023];41(9):669-78. Disponible en: https://www.nature.com/articles/s41440-018-0054-0142. O’Brien E, Sheridan J, O’Malley K. DIPPERS AND NON-DIPPERS. The Lancet [Internet]. 13 de agosto de 1988 [citado 28 de octubre de 2023];332(8607):397. Disponible en: https://www.sciencedirect.com/science/article/pii/S014067368892867X143. Higgins JPT, Li T, Deeks JJ. Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021) [Internet]. Cochrane. 2021 [citado 30 de enero de 2022]. Disponible en: https://training.cochrane.org/handbook/current/chapter-06144. Khader YS, Rice J, John L, Abueita O. Oral contraceptives use and the risk of myocardial infarction: a meta-analysis. Contraception. julio de 2003;68(1):11-7.145. Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives: A meta-analysis. JAMA. 5 de julio de 2000;284(1):72-8.146. Sidney S, Siscovick DS, Petitti DB, Schwartz SM, Quesenberry CP, Psaty BM, et al. Myocardial infarction and use of low-dose oral contraceptives: a pooled analysis of 2 US studies. Circulation. 15 de septiembre de 1998;98(11):1058-63.147. United States Preventive Services Task Force. Guide to clinical preventive services. 2nd ed. International Medical Publishing; 1996. 862 p.148. Judging Confidence. Guidelines for Grading Evidence and Recommendations. Grades of Recommendation Assessment, Development, and Evaluation (GRADE) Working Group. 2003.149. American College of Obstetricians and Gynecologists. Clinical Management Guidelines for Obstetrician–Gynecologists. Use of Hormonal Contraception in Women With Coexisting Medical Conditions. Obstet Gynecol. 2019;206(2):128-50.150. Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep [Internet]. 2016 [citado 14 de febrero de 2024];65. Disponible en: https://www.cdc.gov/mmwr/volumes/65/rr/rr6503a1.htm151. Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. abril de 2001;20(3 Suppl):21-35.AdministradoresBibliotecariosEstudiantesInvestigadoresMaestrosMedios de comunicaciónPúblico generalORIGINAL1024563440.anexos.pdf1024563440.anexos.pdfAnexos Tesis de Maestría en Epidemiología Clínicaapplication/pdf959572https://repositorio.unal.edu.co/bitstream/unal/86465/3/1024563440.anexos.pdf069e72664f9144c83fe3b72a1495daddMD531024563440.2024.pdf1024563440.2024.pdfTesis de Maestría en Epidemiología Clínicaapplication/pdf1099252https://repositorio.unal.edu.co/bitstream/unal/86465/5/1024563440.2024.pdf27230557b8a632a95ea33604ba739c6dMD55LICENSElicense.txtlicense.txttext/plain; charset=utf-85879https://repositorio.unal.edu.co/bitstream/unal/86465/4/license.txteb34b1cf90b7e1103fc9dfd26be24b4aMD54THUMBNAIL1024563440.anexos.pdf.jpg1024563440.anexos.pdf.jpgGenerated Thumbnailimage/jpeg7381https://repositorio.unal.edu.co/bitstream/unal/86465/6/1024563440.anexos.pdf.jpg513c32d3803c55f6f715100976554300MD561024563440.2024.pdf.jpg1024563440.2024.pdf.jpgGenerated Thumbnailimage/jpeg3991https://repositorio.unal.edu.co/bitstream/unal/86465/7/1024563440.2024.pdf.jpg426625149f75fb496b370f36b0d60d03MD57unal/86465oai:repositorio.unal.edu.co:unal/864652024-08-26 23:10:54.447Repositorio Institucional Universidad Nacional de Colombiarepositorio_nal@unal.edu.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